Drug developers and translational scientists evaluating biomarkers in early-phase studies will learn how to leverage advanced technologies to seamlessly transform millions of data points into actionable insights.

Using advanced informatics and visualization tools, innovators can now harmonize disparate sources of biomarker data and warehouse them for more effective on-study use (e.g., dose selection, MoA, safety review meetings) and downstream use (such as interrogating data across clinical studies). Combining advanced technology with biomarker expertise provides flexibility, efficiency, and compliance. Closing the gap in translational research will result in immediate gains and mitigate risks to interim and final study deliverables.

This webinar will feature:

  • Insights into biomarker data trends and challenges
  • Real-world case studies
  • Practical technology-based solutions that can be readily implemented

Featured Speakers

Scott Marshall, PhD

Managing Director, Translational Informatics & Diagnostic Sciences
Precision for Medicine

Extensive industry expertise across the pharmaceutical and biotech space— translational informatics and biomarker R&D —with a focus in precision medicine-guided efforts as well as strategy development and medical device/diagnostic development. Globally responsible for translational informatics R&D efforts. Has led the development of novel methodologies for patient stratification and biomarker guided clinical trial design.

Eric Lai, PhD

Partner
Personalized Science LLC

Dr. Eric Lai is currently a partner at Personalized Science LLC. From 2012 – 2017 he was Senior Vice President and Head of Genomic Medicine at Takeda Pharmaceutical. Before he joined Takeda, he was the SVP and Head of Research and Development at Gen-Probe (now part of Hologic Inc) from 2009 – 2012 and before that he was the VP of Pharmacogenetics at GlaxoSmithKline for over 13 years.

Tobias Guennel, PhD

Senior Director
Translational Informatics and Biometrics

Extensive industry expertise across the pharmaceutical and biotech space—regulatory submissions, translational informatics, biomarker R&D—with a focus in precision medicine-guided efforts as well as strategy development and medical device/diagnostic development. Led numerous analytical R&D efforts and developed novel methodologies to harmonize and analyze data from high-throughput assays, translating it to value at the patient level.


NOW AVAILABLE ON-DEMAND



Register now for this webinar